Oppenheimer has recently initiated Abbott Laboratories (ABT) stock to Outperform rating, as announced on October 8, 2024, according to Finviz. Earlier, on September 19, 2024, Piper Sandler had initiated the stock to Overweight,

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of

Abbott Laboratories just extended its dividend growth streak with a 7.3% hike in the quarterly dividend per share last month.

The company’s projected adjusted diluted EPS for 2025 is between $5.05 and $5.25, marking double-digit growth at the midpoint. Abbott’s first-quarter 2025 adjusted EPS is expected to be between $1.05 and $1.09, further underscoring its momentum heading into the new year.

Mizuho Securities analyst Anthony Petrone maintained a Hold rating on Abbott Laboratories (ABT – Research Report) yesterday. The company’s